The dual role of empagliflozin: Cardio renal protection in T2DM patients

被引：3
|
作者：
Shafiq, Aimen [1 ]
Mahboob, Eman [1 ]
Samad, Muhammad Ammar [1 ]
Rehman, Mohammad Hassam Ur [1 ]
Tharwani, Zoaib Habib [1 ]
机构：
[1] Dow Univ Hlth Sci, Dow Med Coll, Fac Med, Karachi, Pakistan
来源：
ANNALS OF MEDICINE AND SURGERY | 2022年 / 81卷
关键词：
Empagliflozin; Type 2 diabetes mellitus; Cardio protective; Reno protective; Side effects; COTRANSPORTER; 2; INHIBITOR; TYPE-2; DIABETES-MELLITUS; ESTABLISHED CARDIOVASCULAR-DISEASE; BETA-CELL DYSFUNCTION; DOUBLE-BLIND; SGLT2; INHIBITORS; ADD-ON; KIDNEY-DISEASE; OUTCOMES; RISK;
D O I：
10.1016/j.amsu.2022.104555
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Empagliflozin (Jardiance (R)) is an insulin independent antihyperglycemic agent used in treatment of T2D.The drug is a sodium glucose cotransporter-2 (SGLT2) inhibitor approved in USA and Europe and other countries of the world. As empagliflozin demonstrates cardioprotective and Reno protective properties its prime target are patients having CVD and CKD complicated by T2D. This review sheds light on mechanism of action of the drug and with the help of clinical outcomes establishes the use of empagliflozin in T2D patients.Although empagliflozin is a well-tolerated and easy to administer drug, it has some side effects and contraindications which are discussed in the article to help the reader weigh its beneficial effects against its adverse effect and understand its use in clinical medicine.
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Empagliflozin Monotherapy Improves Glucose Control in Drug-Naive Patients With Type 2 Diabetes (T2DM)
    Roden, Michael
    Weng, Jianping
    Eilbracht, Jens
    Delafont, Bruno
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A280 - A280
  • [22] Safety and tolerability of empagliflozin (EMPA) in phase III trials and their extensions in patients with type 2 diabetes (T2DM)
    Roden, M.
    Merker, L.
    Christiansen, A. V.
    Roux, F.
    Hantel, S.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Lund, S. S.
    Hach, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2014, 57 : S325 - S326
  • [23] Aleglitazar—no cardiovascular protection after acute coronary syndrome in patients with T2DM
    Nature Reviews Endocrinology, 2014, 10 (6) : 314 - 314
  • [24] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A69 - A69
  • [25] Safety and Effectiveness of Empagliflozin/Linagliptin FDC in Uncontrolled T2DM Patients with COVID-19 Infection
    Sengupta, Asoktaru
    DIABETES, 2023, 72
  • [26] T2DM patients with depression have higher levels of hyperglycemia and cognitive decline than T2DM patients
    Thummasorn, Savitree
    Apichai, Sopida
    Chupradit, Supat
    Sirisattayawong, Pornpen
    Chaiwong, Pachpilai
    Sriwichaiin, Sirawit
    Pratchayasakul, Wasana
    Chattipakorn, Nipon
    Chattipakorn, Siriporn C.
    PLOS ONE, 2022, 17 (08):
  • [27] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael W.
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [28] Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients
    Abdelgani, Siham
    Khattab, Ahmed
    Adams, John
    Abu-Farha, Mohamed
    Daniele, Guisepe
    Al-Mulla, Fahd
    Del Prato, Stefano
    DeFronzo, Ralph A.
    Abdul-Ghani, Muhammad
    DIABETES CARE, 2023, 46 (05) : 978 - 984
  • [29] Role of miRNAs in Epicardial Adipose Tissue in CAD Patients with T2DM
    Liu, Yang
    Fu, Wenbo
    Lu, Mu
    Huai, Shitao
    Song, Yaqin
    Wei, Yutao
    BIOMED RESEARCH INTERNATIONAL, 2016, 2016
  • [30] Use of sitagliptin in patients with type 2 diabetes (T2DM) and renal insufficiency (RI)
    Scott, Russell
    Hartley, Paul
    Luo, Edmund
    Yee, Jacqueline
    Davies, Michael
    Ferreira, Juan Camilo Arjona
    Williams-Herman, Debora
    DIABETES, 2006, 55 : A462 - A462
12345